Aude Fléchon
Impact in
- Pulmonary and Respiratory Medicine top 0.1%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
Papers in
- Surgery 157
- Testicular diseases and treatments 70
- Bladder and Urothelial Cancer Treatments 66
- Genital Health and Disease 11
- Urinary and Genital Oncology Studies 9
-
- Prostate Cancer Treatment and Research 55
- Renal cell carcinoma treatment 22
- Lung Cancer Treatments and Mutations 5
- Co-authors
- Karim S. Fizazi (32 shared papers)Cora Nanette Sternberg (11 shared papers)Fred Saad (6 shared papers)Johann Sebastian De Bono (3 shared papers)Kurt Miller (2 shared papers)Kim N. Chi (4 shared papers)Mark T. Fleming (1 shared paper)Neal D. Shore (2 shared papers)
- Journals
- Annals of Oncology (53 papers)European Journal of Cancer (23 papers)The Lancet Oncology (15 papers)Journal of Clinical Oncology (12 papers)Clinical Genitourinary Cancer (10 papers)
- Partner nations
- FranceUnited StatesUnited Kingdom
In The Last Decade
Aude Fléchon
253 papers receiving 18.8k citations
Aude Fléchon's Hit Papers
Peers
Comparison fields: 5 of 116
- Pulmonary and Respiratory Medicine 9.4k
- Oncology 3.1k
- Surgery 5.4k
- Cancer Research 674
- Radiology, Nuclear Medicine and Imaging 897
Countries citing papers authored by Aude Fléchon
This map shows the geographic impact of Aude Fléchon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aude Fléchon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aude Fléchon more than expected).
Fields of papers citing papers by Aude Fléchon
This network shows the impact of papers produced by Aude Fléchon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aude Fléchon. The network helps show where Aude Fléchon may publish in the future.
Co-authors
The 25 scholars most cited alongside Aude Fléchon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 274 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Hit paper breakdown → | 2012 | 3736 |
| 2 | Abiraterone and Increased Survival in Metastatic Prostate Cancer Hit paper breakdown → | 2011 | 3648 |
| 3 | Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Hit paper breakdown → | 2017 | 1147 |
| 4 | Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Hit paper breakdown → | 2024 | 628 |
| 5 | Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design Hit paper breakdown → | 2022 | 560 |
| 6 | Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 490 |
| 7 | European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I Hit paper breakdown → | 2008 | 445 |
| 8 | TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors Hit paper breakdown → | 2021 | 441 |
| 9 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 408 |
| 10 | 2018 | 326 | |
| 11 | Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial Hit paper breakdown → | 2020 | 324 |
| 12 | 2013 | 251 | |
| 13 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2023 | 248 |
| 14 | 2012 | 222 | |
| 15 | 2001 | 195 | |
| 16 | 2008 | 193 | |
| 17 | Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses Hit paper breakdown → | 2020 | 190 |
| 18 | 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial Hit paper breakdown → | 2024 | 188 |
| 19 | 2015 | 184 | |
| 20 | 2011 | 177 |
About Aude Fléchon
Aude Fléchon is a scholar working on Surgery, Pulmonary and Respiratory Medicine, Oncology, Internal Medicine and Pharmacology, having authored 274 papers that have together received 19.3k indexed citations. Recurring topics across this work include Testicular diseases and treatments (70 papers), Bladder and Urothelial Cancer Treatments (66 papers), Prostate Cancer Treatment and Research (55 papers), Renal cell carcinoma treatment (22 papers), Cancer Immunotherapy and Biomarkers (11 papers), Genital Health and Disease (11 papers), Urinary and Genital Oncology Studies (9 papers) and Lung Cancer Treatments and Mutations (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (9.4k citations), Oncology (3.1k citations), Surgery (5.4k citations), Cancer Research (674 citations) and Radiology, Nuclear Medicine and Imaging (897 citations). Aude Fléchon has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Karim S. Fizazi, Cora Nanette Sternberg, Fred Saad, Johann Sebastian De Bono, Kurt Miller, Kim N. Chi, Mark T. Fleming, Neal D. Shore, Andrew J. Armstrong and Lynn Seely. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, The Lancet Oncology, Journal of Clinical Oncology and Clinical Genitourinary Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.